UBS Downgrades Allergan to Neutral, Raises Price Target to $203

UBS downgrades Allergan (NYSE:AGN) from Buy to Neutral and raises the price target from $189 to $203.

Benzinga · 11/19/2019 11:16

UBS downgrades Allergan (NYSE:AGN) from Buy to Neutral and raises the price target from $189 to $203.